ViroVet

Leuven, Belgium Founded: 2015 • Age: 11 yrs
Manufacturer and supplier of antiviral drugs for livestock

About ViroVet

ViroVet is a company based in Leuven (Belgium) founded in 2015.. ViroVet has raised $13.63 million across 3 funding rounds from investors including PMV, Aratana and Capricorn Partners. The company has 14 employees as of December 31, 2022. ViroVet offers products and services including PLLAV Vaccines and Antiviral Drugs. ViroVet operates in a competitive market with competitors including Merck Animal Health, TARGAN, VitamFero, Intervacc and Pacific GeneTech, among others.

  • Headquarter Leuven, Belgium
  • Employees 14 as on 31 Dec, 2022
  • Sectors
    Agriculture
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Virovet Nv
Operational Areas
Agriculture → Livestock & Animal Nutrition
Key Metrics
  • Annual Revenue
    $14.97 K (USD)
    -88
    as on Dec 31, 2021
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $13.63 M (USD)

    in 3 rounds

  • Latest Funding Round
    $6.6 M (USD), Series B

    May 28, 2020

  • Investors
    PMV

    & 6 more

  • Employee Count
    14

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of ViroVet

ViroVet offers a comprehensive portfolio of products and services, including PLLAV Vaccines and Antiviral Drugs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Innovative vaccines for viral infections in swine without cold chain.

Fast-acting treatments for respiratory diseases in livestock.

People of ViroVet
Headcount 10-50
Employee Profiles 4
Board Members and Advisors 7
Employee Profiles
People
Erwin Blomsma
CEO
People
Bart Crijns
Director Finance

Unlock access to complete

Board Members and Advisors
people
Ludwig Goris
Director
people
Thomas Beke
Board Member

Unlock access to complete

Funding Insights of ViroVet

ViroVet has successfully raised a total of $13.63M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.6 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $6.6M
  • First Round

    (10 Jan 2017)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2020 Amount Series B - ViroVet Valuation Seventure Partners
Oct, 2017 Amount Series A - ViroVet Valuation Capricorn Partners
Jan, 2017 Amount Series A - ViroVet Valuation PMV
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ViroVet

ViroVet has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include PMV, Aratana and Capricorn Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
Founded Year Domain Location
Investments are directed by Capricorn Partners into European tech ventures.
Founded Year Domain Location
Investments are made in sustainable agriculture and agribusiness.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ViroVet

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ViroVet

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Virovet Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ViroVet

ViroVet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck Animal Health, TARGAN, VitamFero, Intervacc and Pacific GeneTech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Vaccine technology is developed and supplied for livestock animals.
domain founded_year HQ Location
Automated targeted vaccine systems for livestock and aquaculture are developed.
domain founded_year HQ Location
Offers patented immunostimulating vaccines for livestock.
domain founded_year HQ Location
Recombinant vaccines for cattle, equine, and other livestock are developed.
domain founded_year HQ Location
Developer of vaccines and gene delivery platform
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Virovet

Frequently Asked Questions about ViroVet

When was ViroVet founded?

ViroVet was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is ViroVet located?

ViroVet is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.

Is ViroVet a funded company?

ViroVet is a funded company, having raised a total of $13.63M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5.27M, raised on Jan 10, 2017.

How many employees does ViroVet have?

As of Dec 31, 2022, the latest employee count at ViroVet is 14.

What is the annual revenue of ViroVet?

Annual revenue of ViroVet is $14.97K as on Dec 31, 2021.

What does ViroVet do?

Virovet is a biopharmaceutical company engaged in the manufacturing and supply of antiviral drugs for livestock animals catering to the domestic as well as international markets. Its solutions can be used alone or in combination with vaccines to prevent or treat endemic and epizootic viral diseases. The company is using a technology platform to develop a modified live virus (MLV) vaccines. It is also developing antiviral drugs to control and treat respiratory diseases of cattle and swine.

Who are the top competitors of ViroVet?

ViroVet's top competitors include TARGAN, Merck Animal Health and Intervacc.

What products or services does ViroVet offer?

ViroVet offers PLLAV Vaccines and Antiviral Drugs.

Who are ViroVet's investors?

ViroVet has 7 investors. Key investors include PMV, Aratana, Capricorn Partners, flanders.bio, and Seventure Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available